NCT04474821

HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults

Acceptance and Completion Rate of Free HPV Vaccination Among Underserved Adult Patients (Age 18-45)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

This phase IV trial examines the impact of an education program on the human papilloma virus (HPV) and its effects on the acceptance and completion rates of a free HPV vaccination program in underserved adult patients. Participating in the HPV educational program may increase the HPV vaccination rates among low income uninsured adult patients and ultimately prevent HPV related cancers.

Detailed description

PRIMARY OBJECTIVES: I. Determine the acceptability and completion rates of free HPV vaccination among the underserved adult patients at the Volunteer in Medicine Clinic (VIM) in Jacksonville, Florida. II. Determine if an education program on HPV vaccination increases the acceptability of free HPV vaccination among the underserved adult patients at the Volunteer in Medicine Clinic (VIM) in Jacksonville, Florida. III. Determine the baseline prevalence of HPV vaccination completion rates among VIM patients age 18-45. IV. Determine if there are differences in acceptance and completion rates of HPV vaccination, among VIM patients of different sex, age (18-26 versus \[vs\] 27-45), ethnicity or race, following an education program on HPV as part of this protocol participation. VI. Assessing possible barriers for vaccine series completion. VII. Determine if follow up intervention increases completion rate of free HPV vaccine series within 9 months. OUTLINE: Patients receive educational materials on HPV and are asked of their willingness to proceed with the first HPV vaccination. Patients who express interest in receiving the HPV vaccination, then receive the first dose of the HPV vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.

Conditions

• Human Papillomavirus Infection
• Human Papillomavirus-Related Carcinoma

Interventions

Type	Name	Description
OTHER	Educational Intervention	Receive educational materials on HPV
OTHER	Survey Administration	Ancillary studies

Timeline

• Start date: 2020-10-19
• Primary completion: 2025-12-22
• Completion: 2025-12-22
• First posted: 2020-07-17
• Last updated: 2026-01-12

Locations

1 site across 1 country: United States